Lung Cancer Research Studies / Lung Cancer Treatments and Mutations / Lung Cancer Diagnosis and Treatment · Journal article

Therapy for Stage IV Non-Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2026.3.3

Journal of Clinical Oncology · August 17, 2026

Expert Guidance Why this matters to you Expert discussion

A consensus or society position rather than new primary data.

AI Summary

This is version 2026.3.3 of an ASCO Living Guideline for stage IV NSCLC with driver alterations, updated on an eight-week cycle by a standing expert panel that systematically reviews evolving literature. The excerpt provided does not contain specific recommendations, evidence summaries, or clinical findings, only methodological and disclaimer information.

What was studied

Journal article. Patients with stage IV non-small cell lung cancer with driver alterations.

Key findings

Safety

Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.

Who this may help

This guideline provides current recommendations for clinicians managing stage IV NSCLC with driver alterations. Users should consult the full online dynamic version for specific evidence-based recommendations and the latest updates, and should apply recommendations in context of individual patient variation.

Plain-language summary

This is an ASCO clinical practice guideline for stage IV NSCLC with driver alterations, systematically reviewed on an eight-week cycle by expert panel; it provides recommendations for clinical practice rather than reporting original research evidence.

Study design

As stated by the source record.

MethodsLiving guideline reviewed on eight-week cycle by standing expert panel that systematically reviews health literature on continuous basis per ASCO Guidelines Methodology Manual; follows ASCO Conflict of Interest Policy Implementation.

PopulationPatients with stage IV non-small cell lung cancer with driver alterations

Clinical bottom line

Caveats

The provided text is the introductory/methodological section only; no specific clinical recommendations or evidence grades are included in this excerpt.
Underlying evidence summaries, effect sizes, and recommendation strengths are not reported in the source text provided.
The guideline explicitly states it does not substitute for independent clinical judgment or account for individual patient variation.

Evidence assessment

Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.

Study design

insufficient

Guideline methodology; no original study design reported in excerpt.

Directness

strong

Directly addresses stage IV NSCLC with driver alterations in clinical practice.

Consistency

insufficient

Source excerpt does not report underlying evidence synthesis or consistency findings.

Risk of bias

moderate

Follows ASCO Conflict of Interest Policy; COI mitigation stated but specific assessments not detailed.

Sample adequacy

insufficient

Guideline; no primary sample size reported in excerpt.

What is missing. This record has no key findings, reported figures. That is a gap in the analysis, not a judgement about the study.

Source abstract

This guideline has been updated. This ASCO Living Guideline is reviewed on an eight-week cycle. Please see the online dynamic version for the latest updates. Living guidelines are developed for selected topic areas with rapidly evolving evidence that drives frequent change in recommended clinical practice. Living guidelines are updated on a regular schedule by a standing expert panel that systematically reviews the health literature on a continuous basis, as described in the ASCO Guidelines Methodology Manual. ASCO Living Guidelines follow the ASCO Conflict of Interest Policy Implementation for Clinical Practice Guidelines. Living Guidelines and updates are not intended to substitute for independent professional judgment of the treating clinician and do not account for individual variation among patients. See appendix for disclaimers and other important information (Appendix I and Appendix II). Updates are published regularly and can be found on the ASCO Publications website.

Follow from this

Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.

Lung Cancer Research StudiesLyudmila BazhenovaTerri ConneranLung Cancer Treatments and MutationsNofisat IsmailaPaul Wheatley‐PriceJeremy CetnarAntonio CallesLung Cancer Diagnosis and Treatment